TREATMENT OF PROSTATE CANCER IN THE CZECH REPUBLIC IN 2016: OUTCOMES OF WORKSHOPS ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Czech version

Authors: Michaela Matoušková ^1,4,5; Marko Babjuk ^2,4; Jan Krhut ^3,4; Veronika Črepová ⁴
Authors‘ workplace: Urocentrum Praha ¹; Urologická klinika 2. LF a FN Motol, Praha ²; Urologické oddělení FN Ostrava ³; Česká akademie urologie, Česká urologická společnost ČLS JEP ⁴; Onkologická klinika FTN a 1. LF UK, Praha ⁵
Published in: Ces Urol 2017; 21(1): 85-95
Category: Information

Overview

During spring 2016, thirteen workshops on metastatic castration-resistant prostate cancer (mCRPC) were held in larger towns in the Czech Republic, attended by a large group of urologists and oncologists. All the workshops followed a similar scenario, with an initial communication about mCRPC and case report discussion along with seeking consensus in a group of urologists and oncologists divided into teams led by local specialists (a urologist and an oncologist), and a comparison of outcomes of both groups. Consensus outcomes of the workshops are presented in this article.

KEY WORDS:
Malignant prostate cancer, hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer.

Sources

2. Tannock IF, de Witt R, Berry WR, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502–1512.

3. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‑resistant

prostate cancer progressing after docetaxel treatment: a randomised open‑label trial. Lancet 2010; 376: 1147–1154.

4. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration‑resistant

prostate cancer: final overall survival analysis of the COU‑AA-301 randomised, double‑blind, placebo‑controlled phase 3 study Lancet 2012; 13(10): 983–992.

5. Scher HI, Fizzazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. NEJM 2012; 367(13): 1187–1197.

6. Ryan CJ, Smith MR, Fizazi, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‑naive men with metastatic castration‑resistant prostate cancer (COU‑AA-302): final overall survival analysis of a randomised, double‑blind, placebo‑controlled phase 3 study. Lancet 2015; 16(2): 152–160.

7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med 2014; 371: 424–433.

8. Kantoff PW, Gitano CS, Shore ND, et al. Sipuleucel‑T Immunotherapy for Castration‑Resistant Prostate Cancor. N Engl J Med 2010; 363: 411–422.

9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double‑blind study. Lancet 2011; 377: 813–822.

10. Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter radium-223 and Survival in Metastatic prostate Cancer.N Engl J Med 2013; 369: 213–223.

11. James ND, Spears MR, Clarke NW, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the ‘‘Docetaxel Era’’: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67: 1028–1038.

12. Sweney MB, Yu‑Hui BS, Carducci M, el al. Chemohormonal Therapy in Metastatic Hormone‑Sensitive Prostate Cancer. N Engl J Med 2015; 373: 737–746.

13. Ferlay J, Parkin DM, Steliarova‑Foucher E. Estimates of cancer incidence and mortality in Europe in 2008 € J Cancer, 2010; 46(4): 765–781.

14. Berthold DR, Pond GR, Roessner M, et al. TAX-327 investigators. Treatment of hormone‑refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate‑specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research 2008; 14: 2763–2767.

15. Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter radium-223 and Survival in Metastatic prostate Cancer.N Engl J Med 2013; 369: 213–223.

16. Newling DW, Fossa SD, Tunn UW, el al. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). J Urol. 1993 Dec; 150(6): 1840–1844.

17. Mohan R, Panda D. Kinetic Stabilization of Microtubule Dynamics by Estramustine Is Associated with Tubulin Acetylation, Spindle Abnormalities, and Mitotic Arrest. Cancer Res 2008; 68: 6181–6189. Published online August 1, 2008.